Indoleamides are active against drug-resistant Mycobacterium tuberculosis
MetadataShow full item record
Responsible for nearly two million deaths each year, the infectious disease tuberculosis remains a serious global health challenge. The emergence of multidrug- and extensively drug-resistant strains of Mycobacterium tuberculosis confounds control efforts, and new drugs with novel molecular targets are desperately needed. Here we describe lead compounds, the indoleamides, with potent activity against both drug-susceptible and drug-resistant strains of M. tuberculosis by targeting the mycolic acid transporter MmpL3. We identify a single mutation in mmpL3, which confers high resistance to the indoleamide class while remaining susceptible to currently used first- and second-line tuberculosis drugs, indicating a lack of cross-resistance. Importantly, an indoleamide derivative exhibits dose-dependent antimycobacterial activity when orally administered to M. tuberculosis-infected mice. The bioavailability of the indoleamides, combined with their ability to kill tubercle bacilli, indicates great potential for translational developments of this structure class for the treatment of drug-resistant tuberculosis.
Showing items related by title, author, creator and subject.
Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agentsAlsayed, Shahinda SR; Lun, Shichun; Luna, Giuseppe; Beh, Chau Chun; Payne, Alan D; Foster, Neil R; Bishai, William R; Gunosewoyo, Hendra (2020)Our group has previously reported several indolecarboxamides exhibiting potent antitubercular activity. Herein, we rationally designed several arylcarboxamides based on our previously reported homology model and the ...
Preliminary Structure-Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis StrainsOnajole, O.; Pieroni, M.; Tipparaju, S.; Lun, S.; Stec, J.; Chen, G.; Gunosewoyo, Hendra; Guo, H.; Ammerman, N.; Bishai, W.; Kozikowski, A. (2013)Tuberculosis (TB) remains one of the leading causes of mortality and morbidity worldwide, with approximately one-third of the world’s population infected with latent TB. This is further aggravated by HIV coinfection and ...
Dobler, C.; Korver, S.; Batbayar, O.; Oyungtsetseg, S.; Tsolmon, B.; Wright, Cameron; Solongo, B.; Marais, B. (2015)BACKGROUND: Many countries restrict access to directly observed therapy (DOT) for tuberculosis (TB) to government health facilities. More innovative approaches are required to reduce non-adherence, improve patient outcomes ...